This article is more than 5 years old. Information may no longer be current.
ACC launches new LAA closure registry
Click Here to Manage Email Alerts
The American College of Cardiology announced the launch of the LAAO Registry to capture data on a new class of medical devices used in left atrial appendage closure procedures.
The LAAO (Left Atrial Appendage Occlusion) Registry will help assess real-world procedural indications and outcomes as well as short- and long-term safety of procedures and devices for closing the left atrial appendage (LAA), according to a press release issued by the ACC.
The new registry will serve as both the formal FDA-mandated postapproval study for the Watchman device (Boston Scientific) and as a long-term clinical registry for all patients undergoing LAA closure, regardless of the device used, according to the release.
Paul D. Varosy, MD, FACC, FAHA, FHRS, director of cardiac EP at VA Eastern Colorado Health Care System, is the lead physician for the dataset development work group for the registry, according to the release.
“It is exciting that we are launching this registry at the beginning of implementation of this transformative therapy,” Varosy stated in the release. “Clinicians, hospitals, payers and especially patients will benefit from a clear understanding of how these devices are being used in real-world practice. A registry like this can provide important tools in ensuring that the quality of care is as high as it can be for patients receiving these devices.”